NCT
INICIO RECIENTES ARCHIVO COVID-19
INICIO RECIENTES ARCHIVO PUBLICAR INSTRUCCIONES
PARA AUTORES COVID-19 ENTRAR / REGISTRARSE HISTORIA NOSOTROS DIRECTORIO CONTACTO
Intervenciones convenientes

Broncodilatadores
Corticosteroides (CE)
Combinación de CEI y β2 AP





2007, Suplemento 2

2007; 66 (S2)






RESUMEN

Mejorar síntomas respiratorios y calidad de vida relacionada a la salud.

Esta revisión ha cambiado el término de convencionales por la de convenientes. La razón fundamental es que, si bien es cierto, estas intervenciones por convención se consideran parte esencial del tratamiento, ahora debido a que las evidencias actuales indican que su uso es ya no sólo por convencimiento sino también por conveniencia, por tanto les llamaremos convenientes para los pacientes con EPOC. Dentro de este rubro de intervenciones se encuentran los broncodilatadores y los esteroides. Su administración tiene como beneficios convenientes mejorar los síntomas, calidad de vida, disminuir el número de exacerbaciones y hospitalizaciones. Más recientemente se ha propuesto que estos dos tipos de medicamentos podrían impactar además en la sobrevida. Desde nuestra perspectiva la prescripción de estas intervenciones debe hacerse a través de un abordaje progresivo, basados en la sintomatología del paciente (principalmente disnea) y en el grado de obstrucción de la vía aérea.

PALABRAS CLAVE

.

REFERENCIAS

  1. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1: 303-312.

  2. Vestbo J; TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24: 206-210.

  3. Appleton S, Jones T, Poole P, Pilotto L, Adams R, et al. Ipratropium bromide versus short acting b2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 9: CD001387.

  4. Weder MM, Donohue JF. Role of bronchodilators in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 221-234.

  5. Gross NJ, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with in normal subjects. Chest 1989; 96: 984-987.

  6. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006; 533: 36-39.

  7. Maesen FPV, Smeets JJ, Sledsens TJH. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator; a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1506-1513.

  8. Ikeda A, Nishimura K, Koyama H. Comparative dose-response study of three anticholinergic agents and formoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-66.

  9. Noord J, Bantje TH, Eland M, Korducki L, Cornelissen P, on behalf of the Duch Tiotropium Study Group. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.

  10. Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3: 247-268.

  11. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium to chronic obstructive pulmonary disease. Eur Respir Dis 2002; 19: 217-224.

  12. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.

  13. O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.

  14. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta analysis. Thorax 2006; 61: 854-862.

  15. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.

  16. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420-427.

  17. McNicholas WT, Calverley PM, Lee A, Edwards JC. Tiotropium sleep Study in COPD Investigators. Long acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23: 825-831.

  18. Anzueto A, Tashkin D, Menjage S, Kesten S. One year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75-81.

  19. Sansores RH, Ramírez-Venegas A. Guías para el diagnóstico y tratamiento de la Enfermedad Pulmonar obstructiva Crónica. Rev Inst Nal Resp y Naumo Cir Torax. Edición Especial 2003: 20-22.

  20. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium an albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419.

  21. Mahler D, Donohue JF, Barbee RA, Goldman MD, Gross NJ, et al. Efficacy of salmeterol xinafoate in treatment of COPD. Chest 1999; 115: 957-965.

  22. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, et al. Use of long-acting inhaled b2-adrenergic agonist salmeterol xinofoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.

  23. Tashkin DP. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr Opin Pulm Med 2005; 11: 121-128.

  24. Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology 2004; 9: 102-108.

  25. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99: 1511-1520.

  26. Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, et al. The broncodilator response to salmeterol is manteined with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005; 18: 19-22.

  27. O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.

  28. Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, et al. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility. Curr Med Res Opin 2004; 20: 581-586.

  29. Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59: 471-476.

  30. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.

  31. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, et al. Comparisons of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-222.

  32. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18: 397-404.

  33. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603-610.

  34. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence Curr Opin Pulm Med 2006; 12: 132-139.

  35. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2: 334-339.

  36. Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, et al. Effect of low-dose theophylline on airway inflammation in COPD. Respirology 2004; 9: 249-254.

  37. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1818-1823.

  38. Burge PS, Calverly PM, Jones PW, Spencer S, Anderson JA, et al. Randomized, double blind, placebo controlled study of fluticasona propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320: 1297-1303.

  39. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909

  40. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.

  41. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.

  42. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2003; 361: 449-456.

  43. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.

  44. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.

  45. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301-304.

  46. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-1363.

  47. Calverley PM. The role of corticosteroids in chronic obstructive pulmonary disease Semin Respir Crit Care Med 2005; 26: 235-245.

  48. Schmier JK, Halpern MT, Jones ML. Effects of inhaled corticosteroids on mortality and hospitalization in elderly asthma and chronic obstructive pulmonary patients: appraising the evidence. Drugs Aging 2005; 22: 717-729.

  49. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease Thorax 2005; 60: 992-997.

  50. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M. Onset of action of formoterol/budesonide in single inhaler versus formoterol in patients with COPD. Pulm Pharmacol Ther 2004; 17: 121-125.

  51. Reynolds NA, Perry CM, Keating GM. Budesonide/formoterol: in chronic obstructive pulmonary disease. Drugs 2004; 64: 431-41.

  52. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; CD003794.

  53. Decramer M, Ferguson G. Clinical safety of long/acting beta2/agonist and inhaled corticosteroid combination therapy in COPD. COPD 2006; 3: 163-171.

  54. Mapel DW, Hurley JS, Roblin D, Roberts M, Davies KJ, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonist. Respir Med 2006; 100: 595-609.

  55. Calverley P, Pauwels R, Vestbo J, Jones P. Combined salmeterol and fluticasona in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449-456.

  56. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, et al. The efficacy and safety of fluticasone (250 microg)/salmeterol (50 microg) combined in the discus inhaler for the treatment of COPD. Chest 2003; 124: 834-843.

  57. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005; 2: 272-281.

  58. Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005; 27: 531-542.

  59. Centanni S, Di Marco F. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2005; 6: 2525-2534.

  60. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.

  61. Calverley PMA, Anderson JA, Celli B, Ferguson FT, Jenkins C, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.

  62. Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 320-325.

  63. Sin DD, Johnson M, Gan WQ, Man SF. Combination therapy of inhaled corticosteroids and long-acting beta2-adenergics in management of patients with chronic obstructive pulmonary disease. Curr Pharm Des 2004; 10: 3547-3560.

  64. Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta2-agonist and corticosteroids in stable COPD. Chest 2004; 126: 220-237.

  65. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, et al. Can Inhaled Fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulm Med 2006; 6: 3.

  66. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.

  67. Spender S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702 .

  68. Niewoehner DE. Erbland ML, Deupree RH. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947.


2007, Suplemento 2

2007; 66 (S2)